[Comment] Checkpoint inhibitors and aspergillosis in AML: the double hit hypothesis

Despite improvements in outcomes, mortality due to invasive aspergillosis remains high in patients with acute myeloid leukaemia (AML). The poorer survival of patients with invasive aspergillosis and AML is partly due to the suboptimal diagnostic tools available and the relative ineffectiveness of existing antifungal drugs in the setting of ongoing immunosuppression. Because no new antifungals have been commercialised since 2001, the need to develop novel strategies to enhance immune function and synergise with existing antifungal drugs is pressing.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: Comment Source Type: research